Tag: obeticholic acid market size

  • Obeticholic Acid  Market Size to Exceed $1.67 Billion by 2029 | Growth and Industry Trends

    Obeticholic Acid Market Size to Exceed $1.67 Billion by 2029 | Growth and Industry Trends

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Obeticholic Acid Market Grown from 2024 to 2025?

    In recent years, there has been a significant surge in the obeticholic acid market size. Expected to expand from $0.90 billion in 2024 to about $1.02 billion in 2025, the market anticipates a compound annual growth rate (CAGR) of 13.4%. The growth during the historical period is ascribed to several factors. These include the escalating prevalence of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), the expansion of healthcare infrastructures in burgeoning markets, the amplification in liver disease diagnostic practices and screening rates, increased healthcare spending, and substantial investment in liver disease studies.

    What Growth Rate Is Anticipated for the Obeticholic Acid Market in the Coming Years?

    The anticipated growth of the obeticholic acid market size is set to be significant in the upcoming years, with an expected valuation of $1.67 billion in 2029, a 13.1% compound annual growth rate (CAGR). Factors contributing to the predicted growth during this forecast period include an increasing incidence of both primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), a growing demand for innovative treatments for liver disease, heightened awareness of liver diseases and the available remedies, improved access to healthcare globally in emerging markets, along with an increased consciousness regarding liver diseases and potential treatments. Heightened use for NASH treatment, collaborative efforts for continued development, the integration of digital health mechanisms for monitoring and patient adherence, a moving focus towards non-alcoholic fatty liver disease (NAFLD) treatment, improvements in liver disease biomarkers, and advancements in diagnostic technology are amongst the major trends expected in the forecast period.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp

    Who Are the Leading Companies in the Obeticholic Acid Market?

    Major companies operating in the obeticholic acid market are Pfizer Inc., GlaxoSmithKline (GSK), Gilead Sciences Inc., Amgen Inc., Genfit, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, WuXi AppTec, Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Dr. Reddy’s Laboratories, Lupin Limited, Hepalink Pharmaceutical Group5, Alembic Pharmaceuticals, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals, Viva Life sciences, Omgene Life Sciences Pvt. Ltd., Zydus Cadila

    What Are the Key Drivers of the Obeticholic Acid Market?

    The increasing incidence of liver diseases is anticipated to fuel the expansion of the obeticholic acid market in the future. Liver diseases impair the healthy functioning of the liver. The upsurge in liver diseases can be attributed to excessive alcohol intake, which can induce liver inflammation, cirrhosis, and liver failure by damaging liver cells and inhibiting the organ’s healthy operations. Obeticholic acid aids those suffering from liver disease by activating the farnesoid X receptor (FXR). This leads to a reduction in bile acid build-up, a decrease in liver inflammation, and a slowing down of fibrosis progression, ultimately leading to an improvement in liver functionality. For example, the Office for Health Improvement and Disparities, a government department in the UK, stated that in December 2024, premature fatalities due to alcoholic liver disease increased by 3.6% in 2023, amounting to 5,984 compared to 5,776 in 2022. Thus, the escalating incidence of liver diseases is stimulating the growth of the obeticholic acid market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp

    What Are the Key Market Segments in the Obeticholic Acid Industry?

    The obeticholic acid market covered in this report is segmented –

    1) By Product Type: Tablets, Capsules, Other Product Types

    2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications

    Subsegmentss:

    1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets

    2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules

    3) By Other Product Types: Oral Suspensions, Injectable Formulations

    What Are the Latest Trends in the Obeticholic Acid Market?

    Leading businesses in the obeticholic acid market are investing in the innovation of products such as the Farnesoid X receptor (FXR) agonist, aimed to improve liver disease treatments and patient outcomes. An FXR agonist is a compound that triggers the FXR, a nuclear receptor that plays a significant role in moderating the metabolism of bile acid, liver inflammation, and fibrosis. Utilizing FXR agonists enhances liver functionality and they are applied in treating conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For instance, in February 2024, Intercept Pharmaceuticals Inc., an American biopharmaceutical firm, revealed the U.S. Food and Drug Administration’s (FDA) acceptance of its supplemental New Drug Application (sNDA) for the use of Ocaliva in treating individuals with primary biliary cholangitis (PBC). The FDA’s authorization of the sNDA for obeticholic acid (Ocaliva) represents a regulatory step towards affirming its therapeutic advantages in the treatment of PBC.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report

    What Are the Key Regional Markets in the Obeticholic Acid Industry?

    North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22079

    This Report Delivers Insight On:

    1. How big is the obeticholic acid market, and how is it changing globally?

    2. Who are the major companies in the obeticholic acid market, and how are they performing?

    3. What are the key opportunities and risks in the obeticholic acid market right now?

    4. Which products or customer segments are growing the most in the obeticholic acid market?

    5. What factors are helping or slowing down the growth of the obeticholic acid market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Major Drivers Propelling the Growth oh theObeticholic Acid Market Forward: Rising Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Increasing Cases Of NAFLD And Alcohol-Related Liver Conditions

    Major Drivers Propelling the Growth oh theObeticholic Acid Market Forward: Rising Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Increasing Cases Of NAFLD And Alcohol-Related Liver Conditions

    Discover trends, market shifts, and competitive outlooks for the obeticholic acid industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    How Has The Obeticholic Acid Market Size Shifted, And What Is the Outlook Through 2034?

    The market for obeticholic acid has experienced rapid expansion in the past few years. Estimations show that its value is set to increase from $0.90 billion in 2024 to $1.02 billion in 2025, marking a compound annual growth rate (CAGR) of 13.4%. This significant progression during the historical period can be ascribed to various factors including an escalating prevalence of primary biliary cholangitis (PBC), a surging incidence of non-alcoholic steatohepatitis (NASH), advancement in healthcare structure in emerging markets, a rise in screening rates and diagnosis of liver disease, increasing expenditure on healthcare, and substantial investment in research related to liver disease.

    The market size for obeticholic acid is projected to experience swift expansion in the forthcoming years, with an estimated value of $1.67 billion by 2029 and a compound annual growth rate (CAGR) of 13.1%. This growth projection for the forecast period is largely the result of the escalating incidents of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), augmented demand for novel treatments for liver diseases, increasing consciousness about liver diseases and their respective treatments, an expansion of worldwide healthcare services in developing markets, and growing knowledge about liver diseases and their potential treatments. Dominant trends for the forecast period comprise of acceptance for NASH treatment, alliances, and partnerships for further progress, incorporation of digital health instruments for monitoring and adherence, a move towards non-alcoholic fatty liver disease (NAFLD) treatment, progression in liver disease biomarkers, and diagnostic technologies.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Obeticholic Acid Market?

    The escalating incidence of liver afflictions is anticipated to fuel the expansion of the obeticholic acid market. Liver maladies are ailments that obstruct the normal functioning of the liver. The escalating incidence of these diseases is attributable to overconsumption of alcohol, which could induce liver inflammation, cirrhosis, and liver failure by damaging liver cells and hindering its normal functioning. Obeticholic acid benefits patients with liver disease by triggering the farnesoid X receptor (FXR), which lowers bile acid buildup, mitigating liver inflammation and decelerating the progression of fibrosis, thereby enhancing liver function. As an example, the Office for Health Improvement and Disparities, a UK government agency, reported in December 2024, that in 2023 there was a 3.6% increase in premature deaths from alcoholic liver disease, reaching 5,984, up from 5,776 in 2022. Hence, the escalating incidence of liver diseases is driving the expansion of the obeticholic acid market.

    Which Key Market Segments Comprise the Obeticholic Acid Market and Drive Its Revenue Growth?

    The obeticholic acid market covered in this report is segmented –

    1) By Product Type: Tablets, Capsules, Other Product Types

    2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications

    Subsegmentss:

    1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets

    2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules

    3) By Other Product Types: Oral Suspensions, Injectable Formulations

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp

    Which Areas Are Leading Regions in the Obeticholic Acid Market Expansion Across the Globe?

    North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Key Market Trends in theObeticholic Acid Market Over the Coming Years?

    Leading companies in the obeticholic acid market are progressing by creating cutting-edge products like the farnesoid X receptor (FXR) agonist, which aims to elevate the treatment of liver disease and enhance patient results. An FXR agonist is a substance that activates the FXR, a nuclear receptor that plays a key role in the adjustment of bile acid metabolism, inflammation, and fibrosis in the liver. FXR agonists serve to better liver performance and are employed in managing illnesses like primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For example, in February 2024, Intercept Pharmaceuticals Inc., a biopharmaceutical organization based in the US, proclaimed that the U.S. Food and Drug Administration (FDA) has recognized its additional New Drug Application (sNDA) for Ocaliva for treating people with PBC. The endorsement of the additional sNDA for obeticholic acid (Ocaliva) by the FDA represents regulatory advancement in approving its therapeutic advantages in treating PBC.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report

    How Is the Obeticholic Acid Market Conceptually Defined?

    Obeticholic acid is a medication primarily used in the treatment of liver diseases, especially for patients with primary biliary cholangitis (PBC), a chronic liver disease. It is a synthetic bile acid that works by activating a receptor called the farnesoid X receptor (FXR), which helps to regulate bile acid production, liver function, and inflammation.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22079

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Obeticholic Acid Global Market Report 2025  Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    Obeticholic Acid Global Market Report 2025 Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    Which Major Market Drivers Are Expected to Boost the Growth Potential of the Obeticholic Acid Market?

    The increasing incidence of liver ailments is set to boost the expansion of the obeticholic acid market in the near future. Liver diseases, which impede proper liver functioning, are on the rise due to extensive alcohol intake, causing liver cell damage, inflammation, cirrhosis, and even liver failure. Obeticholic acid can assist those battling liver disease by activating the farnesoid X receptor (FXR), which lessens bile acid pile-up, reduces liver inflammation, and curtails fibrosis development, ultimately enhancing liver performance. For example, in December 2024, the UK government’s Office for Health Improvement and Disparities reported a 3.6% increase in premature deaths due to alcoholic liver disease in 2023, with the total rising to 5,984 from 5,776 in 2022. Hence, the growing incidence of liver diseases underlines the growth of the obeticholic acid market.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp

    #What Long-Term Growth Rate is Expected for the Obeticholic Acid Market Between 2025 and 2034?

    The dimension of the obeticholic acid market has been expanding at a rapid pace in recent years. Its market value is projected to climb from $0.90 billion in 2024 to $1.02 billion in 2025, with a compound annual growth rate (CAGR) of 13.4%. This significant progress in the historical period can be traced back to several factors such as the growing occurrence of primary biliary cholangitis (PBC), the escalation in non-alcoholic steatohepatitis (NASH) incidents, the development of healthcare infrastructure in emerging markets, the surge in diagnosis and screening of liver diseases, increased healthcare spending, and greater investment in research on liver diseases.

    The market for obeticholic acid is projected to witness significant growth in the forthcoming years, expanding to $1.67 billion by 2029 with a CAGR of 13.1%. This market surge during the forecast period can be credited to the rising cases of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), increased demand for novel treatments for liver diseases, heightened awareness of liver ailments and their available treatments, broadening of global healthcare availability in emerging economies, and growing consciousness about liver conditions and viable treatments. Key trends anticipated in this period are the adoption of obeticholic acid for NASH therapy, partnerships for additional development, incorporation of digital health tools for tracking and adherence, a transition towards non-alcoholic fatty liver disease (NAFLD) treatment, progression in biomarkers for liver disease, and advancements in diagnostic technologies.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22079

    What Are the Key Market Innovations in the Obeticholic Acid Market Over the Coming Years?

    Leading businesses in the obeticholic acid industry are inventing novel products, including farnesoid X receptor (FXR) agonist, to optimize the management of liver disease and advance patient outcomes. The FXR agonist is a substance that triggers the FXR, a nuclear receptor that plays a crucial role in controlling bile acid metabolism, inflammation, and fibrosis within the liver. They contribute to enhancing liver function and are implemented in therapies for ailments such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For example, as of February 2024, Intercept Pharmaceuticals Inc., a biopharmaceutical company from the United States, reported that the U.S. Food and Drug Administration (FDA) has acknowledged its supplemental New Drug Application (sNDA) for Ocaliva, intended for the treatment of individuals suffering from primary biliary cholangitis (PBC). This recognition of the supplemental New Drug Application (sNDA) for obeticholic acid (Ocaliva) by the FDA indicates regulatory advancements in affirming its clinical advantages in managing PBC.

    Who Are the Top Companies Driving Innovation and Growth in theObeticholic Acid Market?

    Major companies operating in the obeticholic acid market are Pfizer Inc., GlaxoSmithKline (GSK), Gilead Sciences Inc., Amgen Inc., Genfit, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, WuXi AppTec, Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Dr. Reddy’s Laboratories, Lupin Limited, Hepalink Pharmaceutical Group5, Alembic Pharmaceuticals, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals, Viva Life sciences, Omgene Life Sciences Pvt. Ltd., Zydus Cadila

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report

    Which Key Market Segments Comprise the Obeticholic Acid Market and Drive Its Revenue Growth?

    The obeticholic acid market covered in this report is segmented –

    1) By Product Type: Tablets, Capsules, Other Product Types

    2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

    3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications

    Subsegmentss:

    1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets

    2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules

    3) By Other Product Types: Oral Suspensions, Injectable Formulations

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp

    Which Regions Are Emerging as Leaders in the Obeticholic Acid Market?

    North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Obeticholic Acid Market 2025, By The Business Research Company:

    Food Acidulants Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/food-acidulants-global-market-report

    Feed Acidifiers Global Global Market Report 2024

    Glutamic Acid Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/glutamic-acid-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: